Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety, tolerability, and pharmacokinetics study of GRC 17536 in healthy adults and elderly volunteers
NL-OMON38062Phase 1Active, not recruiting
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GRC-17536 in acute pain, chronic pain, asthma and 2 more (3 arms), sponsored by Glenmark Pharmaceuticals SA. Primary endpoints: Plasma pharmacokinetics of GRC 17536, Urine pharmacokinetics of GRC 17536 and 9 more. Started Aug 2011; status: active, not recruiting.
02
Drugs
GRC-17536
03
Conditions
acute painchronic painasthmachronic obstructive pulmonary disease (COPD)cough
Beyond the preview
Go deeper on NL-OMON38062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38062.